Jeil Pharmaceutical Co.,Ltd (KRX: 271980)
South Korea
· Delayed Price · Currency is KRW 14,880
+250 (1.71%)
Oct 8, 2024, 3:30 PM KST
Jeil Pharmaceutical Co.,Ltd Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -35,739 | 5,005 | -13,091 | -12,473 | 6,916 | -10,239 |
| Depreciation & Amortization | 10,549 | 9,767 | 8,886 | 9,133 | 8,993 | 7,747 |
| Loss (Gain) From Sale of Assets | 2.52 | -0.53 | -9.99 | -30 | - | -2.73 |
| Asset Writedown & Restructuring Costs | - | - | - | -607.15 | - | - |
| Loss (Gain) From Sale of Investments | 201.1 | 201.1 | -2,065 | -189.64 | -67 | -72.28 |
| Loss (Gain) on Equity Investments | -80.25 | -815.1 | 142.25 | -1,801 | -653.05 | -109.43 |
| Stock-Based Compensation | 745.33 | 578.03 | 472.48 | 163.17 | 80.04 | - |
| Provision & Write-off of Bad Debts | -492.05 | -2,096 | -370.58 | 1,626 | 127.48 | -397.88 |
| Other Operating Activities | 34,910 | 3,069 | 6,044 | 8,663 | 5,345 | 10,467 |
| Change in Accounts Receivable | -11,750 | -10,856 | -7,984 | 10,157 | 161.51 | 14,232 |
| Change in Inventory | -3,373 | -10,575 | 3,562 | 6,334 | -26,618 | 4,237 |
| Change in Accounts Payable | -169.93 | -7,620 | -1,664 | 9,625 | -6,487 | 4,791 |
| Change in Other Net Operating Assets | 2,203 | 8,362 | -9,069 | -11,498 | -6,844 | -1,694 |
| Operating Cash Flow | -2,993 | -4,981 | -15,147 | 19,100 | -19,046 | 28,958 |
| Capital Expenditures | -4,418 | -6,097 | -11,085 | -5,344 | -2,410 | -1,086 |
| Sale of Property, Plant & Equipment | 20.99 | 87.64 | 10 | - | - | 2.73 |
| Sale (Purchase) of Intangibles | -3,755 | -3,436 | -5,873 | 91.43 | -438.27 | -310.04 |
| Investment in Securities | 6,124 | -2,524 | 1,898 | -845.47 | -2,912 | -185 |
| Other Investing Activities | 425.88 | 51.01 | 126.46 | 60.95 | 183.77 | 82 |
| Investing Cash Flow | -1,602 | -11,919 | -12,924 | -8,037 | -5,577 | -1,146 |
| Short-Term Debt Issued | - | 24,196 | 16,410 | - | 24,419 | 5,000 |
| Total Debt Issued | 2,062 | 24,196 | 16,410 | - | 24,419 | 5,000 |
| Short-Term Debt Repaid | - | - | - | -6,253 | - | -11,380 |
| Long-Term Debt Repaid | - | -4,702 | -7,448 | -8,343 | -7,987 | -6,339 |
| Total Debt Repaid | -2,230 | -4,702 | -7,448 | -14,596 | -7,987 | -17,718 |
| Net Debt Issued (Repaid) | -167.42 | 19,494 | 8,962 | -14,596 | 16,433 | -12,718 |
| Repurchase of Common Stock | - | - | -396.98 | -810.02 | -314.88 | -2,995 |
| Dividends Paid | -728.38 | -728.38 | -947.74 | -1,022 | -1,023 | -875.45 |
| Other Financing Activities | -53.05 | -0 | 26,001 | 27,498 | 38 | - |
| Financing Cash Flow | -948.85 | 18,766 | 33,618 | 11,069 | 15,133 | -16,589 |
| Foreign Exchange Rate Adjustments | 231.93 | -321.57 | -63.8 | -62.04 | -131.82 | -202.62 |
| Miscellaneous Cash Flow Adjustments | 0 | - | -0 | -0 | -0 | - |
| Net Cash Flow | -5,311 | 1,545 | 5,483 | 22,070 | -9,622 | 11,020 |
| Free Cash Flow | -7,410 | -11,077 | -26,232 | 13,756 | -21,457 | 27,872 |
| Free Cash Flow Margin | -1.06% | -1.52% | -3.63% | 1.96% | -3.10% | 4.15% |
| Free Cash Flow Per Share | -508.55 | -760.21 | -1799.81 | 941.63 | -1468.17 | 1899.30 |
| Cash Interest Paid | 4,415 | 4,255 | 1,805 | 921.03 | 1,052 | 1,226 |
| Cash Income Tax Paid | 103.74 | 1,643 | -877.05 | 3,540 | 6,960 | 5,069 |
| Levered Free Cash Flow | -39,374 | 2,881 | 4,052 | 20,240 | -21,666 | - |
| Unlevered Free Cash Flow | -35,638 | 6,652 | 5,933 | 21,469 | -20,997 | - |
| Change in Net Working Capital | 24,747 | -862.86 | -22,337 | -24,077 | 34,907 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.